Loading presentation...

Present Remotely

Send the link below via email or IM

Copy

Present to your audience

Start remote presentation

  • Invited audience members will follow you as you navigate and present
  • People invited to a presentation do not need a Prezi account
  • This link expires 10 minutes after you close the presentation
  • A maximum of 30 users can follow your presentation
  • Learn more about this feature in our knowledge base article

Do you really want to delete this prezi?

Neither you, nor the coeditors you shared it with will be able to recover it again.

DeleteCancel

Hanover Draft 1

No description
by

John Barlow

on 22 March 2017

Comments (0)

Please log in to add your comment.

Report abuse

Transcript of Hanover Draft 1

“Maximally reducing LDL-C levels with Repatha®, beyond what is possible with the current best therapy alone, leads to a further reduction in major cardiovascular events, including heart attacks, strokes and coronary revascularisations”
During ACC2.8 million impressions from 291 Twitter
mentions of Amgen or Repatha from 184 users
Peak of 170 tweets at time of Fourier results
57% of tweets from those of high authority
On the one hand...

During ACC there were 50,573 tweets about ACC
702 tweets an hour!
Studied in 27,564 patients over 2.2 years in the Fourier trial:
Repatha® reduced the risk of deaths, heart attacks and strokes by 20% compared with standard treatment with statin drugs
A 15% reduction in the risk of the extended MACE composite endpoint was seen, which included hospitalisation for unstable angina, coronary revascularisation, heart attack, stroke or cardiovascular death.
Repatha® reduced the rate of heart attacks by 27% and stroke by 21%
It reduced stents and heart bypass procedures by 22%
No significant difference was seen for hospitalisations for unstable angina or cardiovascular death
" 'Huge advance' in fighting world's biggest killer "
" Powerful new cholesterol drug helps statins slash the risk of heart attack: Medication could save thousands of lives every year "
" HEART ATTACK DRUGS BOOST New wonder drug can ' slash risk of heart attack, stroke or death by QUARTER ' compared with just statins "
" Mixing new drug with statins can reduce risk of heart attack "
" New drug that can 'switch off' heart disease could cut death rates by a FIFTH "
On the other hand...
" Did Amgen's Repatha cut CV risks enough to make it cost-effective? Analysts say no "
" Repatha outcomes data "less than stellar"
Analysts underwhelmed by latest results on Amgen's drug despite it seeing some improvements "
" A Heart Attack-Prevention Drug Disappoints...Wall Street "
" Amgen Drug Prevents Heart Attacks, Not Deaths, Disappointing Experts "
" Amgen cholesterol drug cuts heart attack, stroke risk but shares fall "
Hot on the heels...
" BRIEF-Regeneron and Sanofi to present new phase 3 praluent (alirocumab) injection clinical trial analyses at ACC.17 Scientific Sessions. "
" In light of Fourier data, what future for Alnylam and TMC's PCSK9 inclisiran? "
" Praluent's cardiovascular benefit ral ODYSSEY is expected to read out in December 2017 "
Top topics associated with Amgen and Repatha at ACC
Top hashtags associated with Amgen and Repatha at ACC
Buzz cloud associated with Amgen and Repatha at ACC
Hot on the heels...
ACC topics
ACC hashtags
ACC Buzz cloud
Full transcript